Why Is Everyone Ignoring Gilead Stock’s High Cash Yield?

Gilead Sciences (GILD) generated free cash flow equal to 7.1% of its market value over the last twelve months. The median S&P 500 company yielded just 4.5% over the same period. A yield that high means one of two things: the business is either trading at a steep discount, or the market expects it to shrink. So why are investors paying so little for Gilead’s cash?

Why Gilead’s Cash Matters To You As An Owner

Free cash flow represents the capital a business retains after covering its running costs and its spending on plants and equipment. As a shareholder, you own a stake in that generated cash regardless of whether Gilead pays it out. The money that stays inside the company remains yours, much like its profit. When the broader market recognizes that cash accumulation, the share price tends to follow suit, particularly when those reserves are growing.

Gilead Relies Heavily On One HIV Drug

A single HIV drug, Biktarvy, generated $14.3 billion of Gilead’s $29.4 billion in fiscal 2025 revenue. The company turns a significant portion of those sales into operating profit. In fact, its operating margin over the last twelve months stood at 38.5%, outpacing the 18.5% margin for the S&P 500. It also spends little on physical plants and equipment, putting about 4% of its operating cash toward those costs.

That cash output is expanding. Free cash flow reached $12.9 billion over the last twelve months, up from $9.4 billion a year earlier. The metric has remained positive across every twelve-month period of the last three years. Revenue trended upward as well, growing 5.5% in the latest twelve months after a 3.8% increase the year prior. This does not resemble a shrinking enterprise.

Gilead does carry debt, and a portion of its cash must service those obligations before shareholders see any benefit. Net debt sits at 12.6% of the company’s market value. When measured against the combined total of market value plus that debt, the cash yield drops to 6.3% instead of 7.1%. Still, Gilead can afford its interest payments. Before the $11.2 billion acquisition charge, operating profit covers the company’s interest bill 11.7 times over. Free cash flow of $12.9 billion also far exceeds about $1.0 billion of yearly interest.

What Is Shrinking Outside Gilead’s HIV Drugs?

The likeliest reason for the discounted cash yield is Gilead’s dependence on HIV treatments, coupled with declines in two separate business segments outside of HIV: Veklury and cell therapy. During its fiscal Q2 2026 earnings call in August, management lowered the full-year sales forecast for Veklury to about $300 million, down from about $600 million. Cell therapy sales also fell 14% from a year earlier during that quarter, with management pointing to market competition.

Management says its aim is to diversify, and Gilead is acquiring new drug programs to achieve that goal. The company booked $11.2 billion in expenses during the quarter for outside research programs, mostly through acquisitions. Despite maintaining a high operating margin, Gilead reported a net loss of $3.2 billion over the last twelve months. Consequently, the stock has no meaningful P/E.

Yet management stated that it does not currently expect further sizable acquisitions in 2026. At the same time, the company raised its forecast for 2026 HIV sales growth to a range between 9% and 10%, up from 8%.

Going forward, Gilead still has to show that its cash will keep growing despite the contraction in Veklury and cell therapy, and that operating profit will continue covering its interest bill. The company’s full-year 2026 results will speak to both issues. If HIV sales growth reaches the 9% to 10% management now guides for 2026, it would show that Gilead’s largest business is still expanding.

Does This Mean You Should Act On GILD?

Our purpose is to inform you with unique data so you make the right investment decisions. That said, betting on a single stock is always risky, no matter which direction you choose.

There is a smarter approach. Since its inception, the Trefis High Quality (HQ) Portfolio has returned 105%, beating the benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. And it did so without taking the concentrated risk that comes with do-it-yourself stock picking. If that is how you want to invest, the HQ Portfolio is the place to start.